Silvia Manfrini
Biography
born in Verona 10/6/1964
Curriculum
EDUCATION AND TRAINING
• Dates (from – to) 1984-2000
• Name and type of educational or training institution University of Milan
University of Catania
University of Bari
• Principal subjects / occupational skills covered Therapeutic education in diabetes mellitus
• Qualification awarded Degree in medicine and surgery
Internal medicine specialization
PhD in Health Science Pedagogy
• Level in national classification (if relevant) CONFIRMED RESEARCHER
PUBLICATIONS
1. Effect of calcitriol on bone turnover and osteocalcin in recent-onset type 1 diabetes.
Napoli N, Strollo R, Pitocco D, Bizzarri C, Maddaloni E, Maggi D, Manfrini S, Schwartz A, Pozzilli P; IMDIAB Group.
PLoS One. 2013;8(2):e56488. doi:10.1371/journal.pone.0056488. Epub 2013 Feb 20.
2. Diabetes-related autoantibodies in children with acute lymphoblastic leukemia.
Bizzarri C, Pinto RM, Pitocco D, Astorri E, Cappa M, Hawa M, Giannone G, Palermo A, Maddaloni E, Leslie DR, Pozzilli P; IMDIAB Group.
Diabetes Care. 2012 Mar;35(3):e23. doi: 10.2337/dc11-1946. No abstracts available.
3. Clinical update on the use of immune modulators (antiCD3, GAD, Diapep277, anti-IL1) in type 1 diabetes.
Pozzilli P, Guglielmi C, Maggi D, Carlone A, Buzzetti R, Manfrini S.
Curr Pharma Des. 2011;17(29):3224-8. Review.
4. DiaPep277 peptide therapy in the context of other immune intervention trials in type 1 diabetes.
Tuccinardi D, Fioriti E, Manfrini S, D'Amico E, Pozzilli P.
Expert Opin Biol Ther. 2011 Sep;11(9):1233-40. doi:10.1517/14712598.2011.599319. Epub 2011 Jul 13. Review.
5. Blue eyes as a risk factor for type 1 diabetes.
IMDIAB Group.
Diabetes Metab Res Rev. 2011 Sep;27(6):609-13. doi: 10.1002/dmrr.1214.
6. A novel insulin unit calculator for the management of type 1 diabetes.
Maurizi AR, Lauria A, Maggi D, Palermo A, Fioriti E, Manfrini S, Pozzilli P.
Diabetes Technol Ther. 2011 Apr;13(4):425-8. doi: 10.1089/dia.2010.0190. Epub 2011 Feb 28.
7. Incidence of type 1 diabetes has doubled in Rome and the Lazio region in the 0- to 14-year age-group: a 6-year prospective study (2004-2009).
Bizzarri C, Patera PI, Arnaldi C, Petrucci S, Bitti ML, Scrocca R, Manfrini S, Portuesi R, Buzzetti R, Cappa M, Pozzilli P; Immunotherapy Diabetes (IMDIAB) Group.
Diabetes Care. 2010 Nov;33(11):e140.
8. No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial.
Bizzarri C, Pitocco D, Napoli N, Di Stasio E, Maggi D, Manfrini S, Suraci C, Cavallo MG, Cappa M, Ghirlanda G, Pozzilli P; IMDIAB Group.
Diabetes Care. 2010 Sep;33(9):1962-3.
9. Blood glucose monitoring in the normal population: the PREDICA study.
Napoli N, Costanza F, Di Stasio E, Strollo R, Manfrini S, Cipponeri E, Picardi A, Carrano F, Dell'Anna V, Macino W, Pozzilli P.
Acta diabetol. 2011 Mar;48(1):29-34.
10. Westernization of the Filipino population resident in Rome: obesity, diabetes and hypertension.
Gentilucci UV, Picardi A, Manfrini S, Khazrai YM, Fioriti E, Altomare M, Guglielmi C, Di Stasio E, Pozzilli P.
Diabetes Metab Res Rev. 2008 Jul-Aug;24(5):364-70.
11. The PTPN22 1858T gene variant in type 1 diabetes is associated with reduced residual beta-cell function and worse metabolic control.
Petrone A, Spoletini M, Zampetti S, Capizzi M, Zavarella S, Osborn J, Pozzilli P, Buzzetti R; Immunotherapy Diabetes (IMDIAB) Group.
Diabetes Care. 2008 Jun;31(6):1214-8.
12. Age at diagnosis of type 1 diabetes and the effect of immunomodulatory therapies on residual beta cell function.
Pitocco D, DiStasio E, Crinò A, Manfrini S, Guglielmi C, Visalli N, Suraci C, Matteoli MC, Cavallo MG, Bizzarri C, Pozzilli P; IMDIAB Group.
Horm Metab Res. 2008 Jan;40(1):66-8. Epub 2007 Dec 18.
13. Metabolic factors affecting residual beta cell function assessed by C-peptide secretion in patients with newly diagnosed type 1 diabetes.
Picardi A, Visalli N, Lauria A, Suraci C, Buzzetti R, Merola MK, Manfrini S, Guglielmi C, Gentilucci UV, Pitocco D, Crinò A, Bizzarri C, Cappa M, Pozzilli P.
Horm Metab Res. 2006 Oct;38(10):668-72.
